Champions Oncology, Inc.
CSBR
$8.17
-$0.68-7.68%
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.77% | 16.56% | 11.94% | 7.12% | -5.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.77% | 16.56% | 11.94% | 7.12% | -5.90% |
| Cost of Revenue | -15.70% | 12.24% | -7.96% | -1.20% | 1.95% |
| Gross Profit | 149.93% | 22.32% | 43.31% | 17.77% | -17.82% |
| SG&A Expenses | -7.83% | -17.18% | -9.28% | -1.24% | 5.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.09% | -5.70% | -15.75% | -6.41% | -4.17% |
| Operating Income | 274.58% | 137.44% | 152.08% | 109.57% | -4.84% |
| Income Before Tax | 279.36% | 135.87% | 152.56% | 92.52% | -4.00% |
| Income Tax Expenses | 109.09% | 0.00% | -25.00% | -505.00% | -35.29% |
| Earnings from Continuing Operations | 277.67% | 135.15% | 151.17% | 95.74% | -3.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 277.67% | 135.15% | 151.17% | 95.74% | -3.73% |
| EBIT | 274.58% | 137.44% | 152.08% | 109.57% | -4.84% |
| EBITDA | 333.64% | 176.89% | 184.39% | 148.14% | -2.75% |
| EPS Basic | 276.30% | 134.94% | 150.84% | 95.76% | -3.45% |
| Normalized Basic EPS | 277.98% | 135.64% | 152.21% | 114.14% | -3.76% |
| EPS Diluted | 263.16% | 132.59% | 147.37% | 95.87% | -5.56% |
| Normalized Diluted EPS | 269.78% | 134.59% | 150.60% | 114.14% | -3.76% |
| Average Basic Shares Outstanding | 0.79% | 0.72% | 0.64% | 0.27% | 0.26% |
| Average Diluted Shares Outstanding | 5.67% | 3.85% | 3.97% | 0.27% | 0.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
